Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mark A J Gorris"'
Autor:
Kim Monkhorst, Johannes Textor, Michel M van den Heuvel, Katrien Grünberg, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Lieke L van der Woude, Mark A J Gorris, Inge M N Wortel, Kiek Verrijp, Berber Piet, Willemijn S M E Theelen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to in
Externí odkaz:
https://doaj.org/article/663cd6a76af94357ad61372c788c6ddb
Autor:
Kalijn Bol, Johannes Textor, Carl G Figdor, I Jolanda M de Vries, Lieke L van der Woude, Mark A J Gorris, Kiek Verrijp, Leonie I Kroeze, Avital L Amir, Jelena Meek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 5 (2022)
Background Immune checkpoint inhibitors (ICI) can lead to long-term responses in patients with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or acquire secondary resistance. Previous studies have used primary or m
Externí odkaz:
https://doaj.org/article/97f866204a9743d2b373139e6fe20a1d
Autor:
Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry, Martin Gotthardt, Jelle O. Barentsz, I. Jolanda M. de Vries, Winald R. Gerritsen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c+ myeloi
Externí odkaz:
https://doaj.org/article/4dc02aee961d45088f68d31ad80e605a
Autor:
Yvonne M. Hoeijmakers, Michiel Simons, Johan Bulten, Mark A. J. Gorris, Petronella B. Ottevanger, I. Jolanda M. de Vries, Fred C. G. J. Sweep
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica, 101, 1007-1016
Acta Obstetricia et Gynecologica Scandinavica, 101, 9, pp. 1007-1016
Acta Obstetricia et Gynecologica Scandinavica, 101, 9, pp. 1007-1016
Treatment with antibodies directed against programed-cell death ligand 1 (PD-L1) is a novel therapy for patients with gestational trophoblastic disease. Assessment of PD-L1 expression in tumor tissue is commonly used to identify patients who might be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3c98b221d6512c7e19c16f1c0f0e5f
https://doi.org/10.1111/aogs.14404
https://doi.org/10.1111/aogs.14404
Autor:
Beatriz Subtil, Kirti K. Iyer, Dennis Poel, Lotte Bakkerus, Mark A. J. Gorris, Jorge Cuenca Escalona, Koen van den Dries, Alessandra Cambi, Henk M. W. Verheul, I. Jolanda M. de Vries, Daniele V. F. Tauriello
Publikováno v:
Frontiers in Immunology, 14:1105244. Frontiers Media S.A.
Frontiers in Immunology, 14
Frontiers in Immunology, 14
Colorectal cancer (CRC) remains one of the most aggressive and lethal cancers, with metastasis accounting for most deaths. As such, there is an unmet need for improved therapies for metastatic CRC (mCRC). Currently, the research focus is shifting tow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e2426d19716bd7aa0888cb1afbe10d
https://pure.eur.nl/en/publications/ecf8b1dc-088b-4bb0-b4c2-f8ee8c1630c6
https://pure.eur.nl/en/publications/ecf8b1dc-088b-4bb0-b4c2-f8ee8c1630c6
Autor:
Sandra van Wilpe, Shabaz Sultan, Mark A. J. Gorris, Diederik M. Somford, Heidi V. N. Kusters-Vandevelde, Rutger H. T. Koornstra, Winald R. Gerritsen, Michiel Simons, Antoine G. van der Heijden, I. Jolanda M. de Vries, Niven Mehra
Publikováno v:
Cancer Immunology Immunotherapy, 72, 137-149
Cancer Immunology Immunotherapy, 72, 1, pp. 137-149
Cancer Immunology Immunotherapy, 72, 1, pp. 137-149
Background Whereas neoadjuvant cisplatin-based chemotherapy (NAC) followed by a radical cystectomy remains the standard treatment for patients with muscle-invasive bladder cancer (MIBC), increasing evidence suggests that checkpoint inhibitors, either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ce1099f59d9b44a66dfe49ccf0e4a6f
http://hdl.handle.net/2066/287048
http://hdl.handle.net/2066/287048
Autor:
Thijs Roelofsen, Christina Wefers, Mark A. J. Gorris, Johannes C. Textor, Leon F. A. G. Massuger, I. Jolanda M. de Vries, Anne M. van Altena
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Despite advances in therapy, ovarian cancer remains the most lethal gynecological malignancy and prognosis has not substantially improved over the past 3 decades. Immunotherapy is a promising new treatment option. However, the immunosuppressive cance
Externí odkaz:
https://doaj.org/article/f4bc482aa35d42c5b69821664d9efc57
Autor:
Lieke L van der Woude, Mark A J Gorris, Inge M N Wortel, Jeroen H A Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grünberg, Michel M van den Heuvel, Johannes Textor, Carl G Figdor, Berber Piet, Willemijn S M E Theelen, I Jolanda M de Vries
Publikováno v:
Journal for Immunotherapy of Cancer, 10
Journal for Immunotherapy of Cancer, 10, 10
Journal for Immunotherapy of Cancer, 10, 10
BackgroundImmunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f72befe4acddd9e0159627d71ac430c
http://hdl.handle.net/2066/283861
http://hdl.handle.net/2066/283861
Autor:
Mark A J Gorris, Lieke L van der Woude, Leonie I Kroeze, Kalijn Bol, Kiek Verrijp, Avital L Amir, Jelena Meek, Johannes Textor, Carl G Figdor, I Jolanda M de Vries
Publikováno v:
Journal for Immunotherapy of Cancer, 10, 1-12
Journal for Immunotherapy of Cancer, 10, 5, pp. 1-12
Journal for Immunotherapy of Cancer, 10, 5, pp. 1-12
BackgroundImmune checkpoint inhibitors (ICI) can lead to long-term responses in patients with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or acquire secondary resistance. Previous studies have used primary or me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586e4a82bca71d3925c32ffcd0ffafb3
https://doi.org/10.1136/jitc-2021-004329
https://doi.org/10.1136/jitc-2021-004329
Autor:
Sandra van Wilpe, Donjetë Simnica, Peter Slootbeek, Thomas van Ee, Samhita Pamidimarri Naga, Mark A. J. Gorris, Lieke L. van der Woude, Shabaz Sultan, Rutger H. T. Koornstra, Inge M. van Oort, Winald R. Gerritsen, Leonie I. Kroeze, Michiel Simons, Geert J. L. H. van Leenders, Mascha Binder, I. Jolanda M. de Vries, Niven Mehra
Publikováno v:
Oncoimmunology, 11
Oncoimmunology, 11, 1
OncoImmunology, 11(1):2094133. Landes Bioscience
Oncoimmunology, 11, 1
OncoImmunology, 11(1):2094133. Landes Bioscience
Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4886e27291643e575d0b171fa8fc87f
https://doi.org/10.1080/2162402X.2022.2094133
https://doi.org/10.1080/2162402X.2022.2094133